Add Company
Join Now

VGXI Revenue and Competitors

License our Company Data API

Conroe, TX USA

Location

N/A

Total Funding

Biotech

Industry

Employee Data

  • VGXI has 113 Employees.(i)
  • VGXI grew their employee count by 19% last year.

VGXI's People

NameTitleEmail/Phone
1
Chief Commercial OfficerReveal Email/Phone
2
Chief Operating OfficerReveal Email/Phone
3
Chief Commercial OfficerReveal Email/Phone
4
Chief Accounting OfficerReveal Email/Phone
5
Director MarketingReveal Email/Phone
6
Director Quality ControlReveal Email/Phone
7
Sr. Director FacilitiesReveal Email/Phone
8
Sr. Director, Human ResourcesReveal Email/Phone
9
Director ManufacturingReveal Email/Phone
10
Director, MarketingReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M11-8%N/AN/A
#2
$14.9M96-6%N/AN/A
#3
$15.2M983%$1.8MN/A
#4
$1.6M100%N/AN/A
#5
$3.4M220%N/AN/A
#6
$2.8M1850%N/AN/A
#7
$7.4M48-2%N/AN/A
#8
$0.8M50%N/AN/A
#9
$1.6M100%N/AN/A
#10
$16.3M10562%N/AN/A
Add Company

What Is VGXI?

VGXI is a leader in plasmid DNA contract manufacturing, with 20+ years of experience providing high quality products to biomedical researchers worldwide. We support clients that develop DNA vaccines, immunotherapies, cell therapies, and gene therapies. VGXI’s manufacturing process and quality controls are coupled to a continuous, low-shear AIRMIX® patented lysis technology, and optimized purification processes that provide highly supercoiled plasmid and exceptional purity. VGXI’s portfolio includes high quality plasmid for preclinical research, Highly Documented (HD) plasmid as a critical raw material for GMP viral vector production or pharm/tox studies, cGMP plasmid DNA for clinical through commercial supply, and custom services.

keywords:N/A

N/A

Total Funding

113

Number of Employees

N/A

Revenue (est)

19%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$28.9M1184%N/A
#2
$126.9M1204%N/A
#3
$35.4M122-33%N/A
#4
$46.6M1325%N/A
#5
$7.5M1337%N/A